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Introduction: The amyloid-β42 (Aβ42) peptide plays a crucial role in the pathogenesis of Alzheimer’s disease (AD),
the most common neurodegenerative disorder affecting the elderly. Over the past years, several approaches and
compounds developed for the treatment of AD have failed in clinical studies, likely in part due to their low penetration
of the blood–brain barrier (BBB). Since nanotechnology-based strategies offer new possibilities for the delivery of drugs
to the brain, this technique is studied intensively for the treatment of AD and other neurological disorders.
Methods: The Aβ42 lowering drug flurbiprofen was embedded in polylactide (PLA) nanoparticles by emulsification-
diffusion technique and their potential as drug carriers in an in vitro BBB model was examined. First, the cytotoxic
potential of the PLA-flurbiprofen nanoparticles on endothelial cells and the cellular binding and uptake by endothelial
cells was studied. Furthermore, the biological activity of the nanoparticulate flurbiprofen on γ-secretase modulation as
well as its in vitro release was examined. Furthermore, the protein corona of the nanoparticles was studied as well as
their ability to transport flurbiprofen across an in vitro BBB model.
Results: PLA-flurbiprofen nanoparticles were endocytosed by endothelial cells and neither affected the vitality nor barrier
function of the endothelial cell monolayer. The exposure of the PLA-flurbiprofen nanoparticles to human plasma occurred
in a rapid protein corona formation, resulting in their decoration with bioactive proteins, including apolipoprotein E.
Furthermore, luminally administered PLA-flurbiprofen nanoparticles in contrast to free flurbiprofen were able to modulate
γ-secretase activity by selectively decreasing Aβ42 levels in the abluminal compartment of the BBB model.
Conclusions: In this study, we were able to show that flurbiprofen can be transported by PLA nanoparticles across an
in vitro BBB model and most importantly, the transported flurbiprofen modulated γ-secretase activity by selectively
decreasing Aβ42 levels. These results demonstrate that the modification of drugs via embedding in nanoparticles is
a promising tool to facilitate drug delivery to the brain, which enables future development for the treatment of
neurodegenerative disorders like AD.Introduction
Alzheimer’s disease (AD) is an age-related neurodegenera-
tive disorder currently affecting more than 35 million
people worldwide [1]. To date, the treatment of AD is only
symptomatic and there is no cure for the disease [2]. AD
is characterized by neuronal and synaptic loss, neurofibril-
lary tangle formation and extracellular deposits of
amyloid-β (Aβ) peptides in susceptible brain regions,
which result in learning and memory impairment [3]. Aβ* Correspondence: pietrzik@uni-mainz.de
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2013is generated through the sequential processing of the
amyloid precursor protein (APP) by the β-secretase
(BACE1) and the γ-secretase complex, and occurs in vari-
ous isoforms between 36 and 46 amino acids in length,
with Aβ40 and Aβ42 being the most prevalent variants
[4-6]. Recently, we have demonstrated that APP is also
processed by the metalloprotease meprin β, which might
act as an additional enzyme, responsible for the release of
N-terminal truncated Aβ species and soluble N-terminal
APP fragments, independent of BACE1 [7,8]. According
to the amyloid hypothesis [9-11], abnormal accumulation
or increased generation of Aβ42 peptides in the brain is
a primary event in the pathogenesis of AD [12-14].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blocking its aggregation or enhancing Aβ clearance in the
brain are thought to slow down the progression of the
disease [15].
Besides APP, γ-secretase has more than 50 substrates
with critical functions, such as cell signaling (for example,
the Notch receptor), cell adhesion and apoptosis [16]. In
earlier studies, we were able to demonstrate that the treat-
ment of Chinese hamster ovary (CHO) cells with some
nonsteroidal anti-inflammatory drugs (NSAIDs) such as
indomethacin, ibuprofen and flurbiprofen specifically de-
creased the secretion of the Aβ42 peptides. This was accom-
panied by an increase of other Aβ isoforms (for example,
Aβ37 and Aβ38), indicating that NSAIDs subtly altered γ-
secretase activity without significant impairment of other
APP processing pathways or Notch signaling [17]. NSAIDs
exert their principal therapeutic effects, reducing fever, pain
and inflammation, by blocking the cyclooxygenase (COX)-
mediated synthesis of inflammatory prostaglandins [18].
However, some NSAIDs were shown to selectively lower
Aβ42 production in vitro and in mouse models of AD, inde-
pendently of COX activity [17,19]. Later, small molecules
with the ability to lower Aβ42 production without altering
overall γ-secretase activity were termed γ-secretase modu-
lators (GSM) [20]. Recently, the clinical development of the
Aβ42 lowering agent tarenflurbil, the COX-inactive R-en-
antiomer of the NSAID flurbiprofen, has been stopped after
failure in a Phase III clinical trial [21]. The results of this
multicenter, randomized, double-blind, placebo-controlled
trial did not show any slowing of cognitive decline after 18
months of treatment with tarenflurbil. While the reasons
for the clinical failure of tarenflurbil are unknown, low
penetration across the blood–brain barrier (BBB) and, con-
sequently, insufficient target engagement in the brain may
be likely explanations [21].
The BBB separates the circulating blood from the cen-
tral nervous system (CNS) and is comprised of endo-
thelial cells, astrocytes and pericytes. Tight junctions
between the endothelial cells are an essential part of the
BBB because they close the intracellular space and limit
the paracellular flux of hydrophilic molecules across the
BBB. The brain endothelial cells express a large number
of specialized transporters and receptors, including car-
riers for glucose and amino acids. Therefore, the BBB
plays a crucial role in the regulation of the constancy of
the internal environment of the brain and is essential for
the supply of the CNS with nutrients. Furthermore, it
protects the brain from the peripheral circulation and
toxic substances and restricts the transport of many
therapeutically important drugs from the blood into the
brain, including Alzheimer drugs, anticancer drugs, anti-
biotics and a wide variety of CNS-active drugs [22-24].
Over the past few years, a number of different strat-
egies have been devised to overcome the BBB such asosmotic opening of the tight junctions, the direct sur-
gical administration of drugs into the brain or the de-
velopment of drug carriers such as liposomes or
nanoparticles [15,25-27]. However, the most notable and
promising progression has been achieved by the use of
nanotechnology. Liposomes as well as solid lipid nano-
particles or different polymeric nanoparticles have been
successfully used for the transport of drugs across the
BBB and into the brain [28]. Compared to free drug
molecules or pro-drugs, the usage of nanoparticles pos-
sesses advantages such as a high drug-loading capacity
of the nanoparticles. Furthermore, the drugs are pro-
tected against chemical or enzymatic degradation. In
addition, nanoparticles can be actively targeted to a tis-
sue via surface modifications of the nanoparticles [29].
In this study, we used polylactide (PLA) as the start-
ing polymer for the nanoparticle preparation. By an
emulsification-diffusion method, racemic flurbiprofen was
embedded in the PLA nanoparticles. We decided to use
flurbiprofen as a candidate substance since flurbiprofen
has already been approved by the Food and Drug Admin-
istration (FDA) and is freely available as an over-the-
counter medicine. We studied the transport of nanoparti-
culate flurbiprofen in an in vitro BBB model, and we could
convincingly demonstrate that γ-secretase modulation
in vitro was significantly enhanced after BBB penetration
when flurbiprofen was delivered with nanoparticles com-
pared to flurbiprofen alone.
Methods
Reagents and chemicals
Poly(L-lactide) (PLA, viscosity approximetely 1.0 dL/g),
flurbiprofen and polyvinyl alcohol (PVA) were obtained
from Sigma (Steinheim, Germany). Lumogen® F orange
240 was provided by BASF (Ludwigshafen, Germany).
All other reagents were of analytical grade and used as
received.
Nanoparticle preparation
PLA nanoparticles were formed by an emulsification-
diffusion technique. Briefly, 100 mg of PLA, 10 mg of
flurbiprofen and 150 μg of Lumogen® orange were dis-
solved in 2 ml dichloromethane (DCM). For the control
PLA nanoparticles, 100 mg of PLA and 150 μg of Lumo-
gen® orange were dissolved in 2 ml DCM. For both for-
mulations, the organic phase was added to 6 ml aqueous
solution of PVA (2%, w/v). This mixture was homoge-
nized in an ice bath for 30 minutes at 24,000 rpm (Ultra
Turrax®, IKA, Staufen, Germany) and diluted with 6 ml
PVA solution (1%, w/v). DCM was removed by stirring
the emulsion over night at room temperature. Finally,
the particles were collected by centrifugation at 20,000 g
for 10 minutes (Eppendorf, Hamburg, Germany) and
washed twice with purified water before lyophilization.
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For the lyophilization process a freeze-dryer Epsilon 1–4
(Martin Christ Gefriertrocknungsanlagen GmbH, Oster-
ode am Harz, Germany) was used. Aliquots of the nano-
particles suspension (100 μl) were dispensed into 2 ml
Lyovials and diluted with 100 μl trehalose solution (6%,
w/v) as a cryoprotective agent. The freeze-drying cycle
was performed according to an established protocol.
First, the samples were frozen at −40°C for three hours.
In the second step, primary drying was performed at a
temperature of −34°C for 24 hours and a vacuum of 0.05
mbar, followed by a secondary drying phase for 11 hours
at 20°C and a vacuum of 0.025 mbar. At the end of the
drying process the vials were sealed and removed.Nanoparticle characterization
Nanoparticles were analyzed with regard to particle
diameter and polydispersity by photon correlation spec-
troscopy (PCS) and zeta potential was measured by mi-
croelectrophoresis using a Malvern Zetasizer Nano ZS
(Malvern Instruments Ltd., Malvern, UK). Prior to mea-
surement the samples were diluted with purified water.Determination of flurbiprofen loading
The amount of flurbiprofen incorporated into the nano-
particles was determined by a HPLC method in which 1
mg nanoparticles was incubated in 1 ml acetonitrile for
five minutes at room temperature. The sample was cen-
trifuged (20,000 g for 10 minutes) and the chromato-
graphic separation was carried out using aliquots of the
supernatant. The aliquots (20 μl) were injected into a
Phenomenex Gemini NX 250 × 4.6 mm, 5 μm particle,
C18 column (Phenomenex, Aschaffenburg, Germany).
The flow rate was set to 1 ml/minute during the sepa-
ration, with the mobile phase composed of acetonitrile
and 0.1% (v/v) trifluoroacetic acid (57.5: 42.5, v/v). The
eluate was analyzed at a wavelength of 245 nm.In vitro release of flurbiprofen
For each point in time individual samples were prepared
as follows: 1 mg nanoparticles were incubated in 1 ml
phosphate buffer (0.1 mM, pH = 7.5) at 37°C under con-
stant shaking. At defined points in time (0, 0.5, 1, 3, 5, 7,
24 hours) one sample was centrifuged (20,000 g for 10
minutes). The amount of the released drug was deter-
mined in the supernatant by HPLC as described above.Nanoparticles reconstitution
The freeze-dried nanoparticles were always reconstituted
prior to the cell culture experiments. Therefore, 40 mg
nanoparticles were dissolved in 1 ml purified water and
vortexed for two minutes.Cell culture
The mouse brain endothelial cell line bEnd.3 (ATCC,
Manassas, VA, USA) was cultured in DMEM (Gibco,
Darmstadt, Germany) high glucose medium containing
10% fetal bovine serum and 100 U/ml penicillin/strepto-
mycin (Gibco, Darmstadt, Germany). For the exper-
iments, 5 × 104 cells per cm2 were seeded and the
experiments were performed after three days when the
cells were post-confluent. APP751 overexpressing CHO
cells (7WD10) were cultured in DMEM high glucose
medium containing 10% fetal bovine serum, 1 mM so-
dium pyruvate (Gibco, Darmstadt, Germany), 100 U/ml
penicillin/streptomycin and 400 μg/ml geneticin (Calbio-
chem, Nottingham, UK). For the experiments, 3 × 104
cells per cm2 were seeded, and after 24 hours cells were
either treated or co-cultured with the bEnd.3 in the
in vitro BBB model.Measurement of cytotoxicity
The cytotoxicity of free flurbiprofen or PLA-flurbiprofen
nanoparticles was assessed using the alamarBlue® reagent
(Invitrogen, Karlsruhe, Germany). bEnd.3 cells were seeded
on 96-well plates (Greiner, Frickenhausen, Germany) and
after reaching post-confluency, cells were treated with in-
creasing concentrations of free or nanoparticulate flurbipro-
fen, ranging from 25 μM to 750 μM (which corresponded
to approximately 32 μg/cm2 to 942 μg/cm2 nanoparticles).
The unit μg per cm2 refers to the amount of nanoparticles
which are administered to the cells and this unit reflects
possible local sedimentation on the surface of the cells,
which locally might lead to different concentrations. After
72 hours, cells were incubated for another four hours with
1 × alamarBlue® in medium. The absorbance was measured
with an Anthos plate reader 2010 (Anthos Labtec, Salzburg,
Austria) using a 570 nm measurement filter and a 600 nm
reference filter. The cell viability was calculated as percent-
age of absorbance in relation to vehicle control treated cells.Measurement of the transepithelial electrical resistance of
endothelial cells
The transepithelial electrical resistance (TER) was used to
analyze the toxicity of the nanoparticles for endothelial
cells. bEnd.3 cells were seeded on 24-transwell cell cul-
ture inserts (ThinCerts™, Greiner Bio-One, Frickenhausen,
Germany) and placed into the cellZscope® device [30]. The
TER of the cells was measured automatically every hour
under physiological conditions by impedance spectros-
copy. When cells were post-confluent, equal amounts of
drug-loaded and unloaded nanoparticles (approximately
2.4 mg nanoparticles per cm2) were added luminally and
the TER was measured (this concentration corresponds to
750 μM nanoparticulate flurbiprofen).
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bEnd.3 cells were cultured in 24-well plates (Greiner,
Frickenhausen, Germany) and treated with approxi-
mately 100 μg/cm2 PLA-flurbiprofen nanoparticles for
four hours at 37°C. After the incubation, cells were
washed twice with PBS (Invitrogen, Karlsruhe, Germany)
and subsequently trypsinized and harvested. Fixing was
performed with FACS-Fix (10 g/L paraformaldehyde
(PFA) and 8.5 g/L NaCl in PBS, pH 7.4) before flow cy-
tometry analysis. Per sample, 104 cells were counted
using FACSCalibur and CellQuest Pro software (Becton
Dickinson, Heidelberg, Germany). The fluorescent label-
ing of the nanoparticles via Lumogen® F Orange 240
allowed a detection at 524/539 nm. To study the endo-
cytotic uptake of the PLA nanoparticles, bEnd.3 cells
were grown on glass coverslips (Marienfeld, Lauda-
Königshofen, Germany) and treated with approximately
100 μg/cm2 PLA-flurbiprofen nanoparticles at 4°C or
37°C for one hour or four hours. After the incubation,
cells were put on ice and washed with PBS pH2 to re-
move the surface-bound nanoparticles, mimicking the
acidic environment of endosomes where ligands dissoci-
ate from their receptor after internalization [31]. Cells
were fixed with 4% PFA and 0.12 M sucrose in PBS for
10 minutes at room temperature and the cell nuclei
were stained with 2 μM DRAQ5™ (Biostatus Limited,
Leicestershire, UK) for 10 minutes at room temperature.
Samples were embedded in Prolong® Gold antifade re-
agent (Invitrogen, Darmstadt, Germany) and the con-
focal laser scanning microscope (CLSM) study was
performed with a CLSM equipped with ZEN 2008 soft-
ware (LSM 710; Zeiss, Jena, Germany).
Treatment of 7WD10 with nanoparticles
To examine the biological activity of flurbiprofen-loaded
nanoparticles, 7WD10 were treated with free or nanopar-
ticulate flurbiprofen, ranging from 50 μM to 250 μM
flurbiprofen. The administered concentration of the nano-
particles was adjusted to the free flurbiprofen, which
corresponds to approximately 65 μg/cm2 to 317 μg/cm2
nanoparticles. After 48 hours, the supernatants were col-
lected and centrifuged at 18,000 g for 20 minutes at 4°C.
Levels of Aβ were measured by an Aβ specific ELISA.
Transport assay of nanoparticulate flurbiprofen in an
in vitro BBB model
bEnd.3 cells were seeded on 24-transwell cell culture in-
serts. After reaching post-confluency, bEnd.3 cells were
co-cultured with 7WD10 in the lower compartment and
bEnd.3 cells were treated with 300 μM free flurbiprofen
or nanoparticulate flurbiprofen, ranging from 300 μM to
750 μM flurbiprofen, which corresponds to approxi-
mately 380 μg/cm2 to 942 μg/cm2 nanoparticles. After
72 hours, the supernatants of the lower compartmentwere collected and centrifuged at 18,000 g for 20 min-
utes at 4°C. Levels of Aβ were measured by an Aβ spe-
cific ELISA.
Measurement of Aβ species by ELISA
The levels of Aβ40 and Aβ42 peptides were determined using
a cell-based sandwich ELISA assay as described [32]. Briefly,
the monoclonal antibody IC16 (1:250 in PBS, pH 7.2) raised
against amino acids 1 to 15 of the Aβ sequence was used as
a capture antibody. To generate standard curves, synthetic
Aβ40 and Aβ42 peptides (JPT Peptide Technologies, Berlin,
Germany) were used. These Aβ peptides were solubilized in
dimethyl sulfoxide (DMSO) at 10 μg/ml and aliquots were
stored at −80°C. The capture antibody was inclubated over-
night in 96-well high-binding microtiter plates at 4°C. After
the capture antibody was removed, conditioned media sam-
ples (20 μl for detection of Aβ40 and 100 μl for Aβ42) and
freshly diluted Aβ peptide standards (125 to 6,000 pg/ml in
PBS containing 0.05% Tween-20, 1% BSA) were added. Sub-
sequently, C-terminal detection antibodies specific for Aβ40
and Aβ42 labeled with horseradish peroxidase (HRP) using
the Pierce EZ-Link™ Plus Activated Peroxidase kit (Thermo
Fisher Scientific, Rockford, IL, USA) were diluted in PBS
containing 0.05% Tween-20, 1% BSA, added to each well,
and incubated overnight at 4°C. Plates were washed three
times with PBS containing 0.05% Tween-20 and once with
PBS. Then, 50 μl of TMB (3,3',5,5'-Tetramethylbenzidin)
ELISA Peroxidase Substrate (Interchim, Montlucon cedex,
France) was added and incubated for 1 to 10 minutes at
room temperature in the dark. The reaction was stopped by
adding 50 μl of 2 M H2SO4 and the absorbance was mea-
sured using a Paradigm microplate reader (Beckman
Coulter, Krefeld, Germany) at 450 nm. The levels of the
Aβ40 and Aβ42 peptides were normalized to Aβ total (Aβ40
+ Aβ42) and the average of triplicate measurements for
each concentration was normalized to the control condi-
tion (DMSO or unloaded PLA nanoparticles).
Nanoparticle plasma protein binding assay
To obtain human plasma, blood was taken at the ENT
department at the Medical University Mainz from 15 differ-
ent seemingly healthy donors in k2EDTA coated tubes
(Greiner, Frickenhausen, Germany) to prevent blood clot-
ting. The blood samples were labeled anonymously and
could not be traced back to a specific donor. Studies were
approved by the local ethics committee of the University
Medical Center of the Johannes Gutenberg-University of
Mainz, and informed consent was obtained in accordance
with the Declaration of Helsinki. The PLA nanoparticles
were incubated with equal amounts of human plasma for
different time points (5, 15, 30 and 60 minutes), loaded
onto a sucrose cushion (0.7 M in PBS) and centrifuged
through the cushion to separate nanoparticle-protein com-
plexes from plasma (12,000 rpm for 20 minutes at 4°C).
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were eluted from the recovered particles by adding an
equal volume of SDS sample buffer (62.5 mM Tris–HCl
pH 6.8; 2% (w/v) SDS, 10% glycerol, 50 mM dithiothreitol
(DTT), 0.01% (w/v) bromophenol blue) to the pellet and
incubated at 95°C for five minutes. Proteins were separated
on a 12% SDS-polyacrylamide gel. To visualize the kinetic
evolution of the protein corona, the SDS-polyacrylamide
gel was stained with Coomassie brilliant blue R-250 (Bio-
Rad, München, Germany) and protein quantification was
performed using the BioRad Protein Assay (Bio-Rad,
München, Germany). To examine the presence of apolipo-
proteins in the nanoparticle-protein complex, proteins
were transferred onto a polyvinylidene difluoride (PVDF)
membrane. Membranes were blocked with 5% non-fat dry
milk in Tris-buffered saline (TBS) containing 0.01%
Tween-20 and the following antibodies were used: α-
apoA4 (Cell Signaling, Boston, MA, USA ); α-apoE and
rabbit-α-mouse immunoglobulin G (IgG) antibody conju-
gated with HRP (Santa Cruz, Dallas, TX, USA).
Statistical analysis
All graphs and statistics were performed using the
GraphPad Prism 4 software (GraphPad, La Jolla, CA,
USA). Data were analyzed by two-way analysis of vari-
ance (ANOVA) coupled to Bonferroni post-tests for
multiple comparisons. P <0.05 was considered as statisti-
cally significance.
Results
Preparation and characterization of PLA nanoparticles
To investigate a novel approach to deliver potential drugs
against AD into the brain, we established an in vitro BBB
model to analyze the transport and functionality of the
Aβ42 lowering drug flurbiprofen embedded in PLA nano-
particles. The PLA-flurbiprofen nanoparticles were pre-
pared by an emulsification-diffusion method. For the
visualization of the nanoparticles, Lumogen® F Orange 240
(kindly provided by BASF) was added during the prepar-
ation. The particles had a size between 213.6 and 218.1
nm. The amount of incorporated flurbiprofen was deter-
mined by HPLC (Table 1).
Determination of cell toxicity
The cytotoxicity of the PLA-flurbiprofen nanoparticles
was assessed using the alamarBlue® cell viability reagent.
Therefore, post-confluent bEnd.3 cells were incubated
with increasing concentrations of free flurbiprofen orTable 1 Physicochemical characteristics of polylactide (PLA) n
Formulation Mean particle diameter (nm) Polydisp
PLA-flurbiprofen nanoparticles 218.1
PLA nanoparticles 213.6PLA-flurbiprofen nanoparticles. As reported earlier by
us and others, free flurbiprofen has a cytotoxic potential
at concentrations above 300 μM (Figure 1A) [19,33]. In
contrast, nanoparticulate flurbiprofen showed no cyto-
toxic potential (Figure 1B). The toxicity of the nanopar-
ticles was further analyzed by the measurement of their
influence on the integrity of endothelial cells (Figure 2).
Therefore, the TER of the cells was measured by imped-
ance spectroscopy using a cellZscope® device [30]. bEnd.3
were cultured on cell culture inserts and after reaching
post-confluency, cells were treated with 750 μM nanopar-
ticulate flurbiprofen. The nanoparticles showed no inter-
ference with the TER development, even at this high
concentration. Taken together, the cell viability as well as
the integrity of the endothelial cells was not impaired by
the nanoparticulate flurbiprofen and, therefore, any cyto-
toxic effect could be excluded.
Biological activity of nanoparticles
Although we could convincingly demonstrate the toler-
ance of endothelial cells to nanoparticulate flurbiprofen,
we had to establish whether nanoparticulate flurbiprofen
had any biological activity on modulating the γ-secretase
function. Therefore, we first analyzed the in vitro release
of flurbiprofen from the PLA nanoparticles at a physio-
logical pH by incubating 1 mg nanoparticles in 1 ml
phosphate buffer (pH = 7.5) at 37°C. By HPLC, we ob-
served that flurbiprofen is constantly released from the
nanoparticles over time with an initial rapid release
followed by a slower exponential phase (Figure 3). Con-
sequently, we analyzed the influence of nanoparticulate
flurbiprofen on γ-secretase activity using APP overexpress-
ing cells (7WD10). The 7WD10 cells were incubated with
free flurbiprofen or PLA-flurbiprofen nanoparticles (both
ranging from 50 μM to 250 μM). After 48 hours, tissue
culture supernatants were collected and the amounts of
Aβ40 and Aβ42 were measured by an Aβ specific ELISA. As
reported earlier by us and others, free flurbiprofen specific-
ally modulates γ-secretase activity by decreasing the levels
of Aβ42 in a concentration dependent manner whereas the
levels of Aβ40 remained unaffected (Figure 4A) [17,19]. For
the treatment with the PLA-flurbiprofen nanoparticles, the
administered concentration of the nanoparticles was
adjusted to the free flurbiprofen to compare the effects
of the nanoparticulate and the free drug. The nanopar-
ticulate flurbiprofen reduced the amount of the Aβ42
peptides in a concentration dependent manner
(Figure 4B). The levels of Aβ40 remained unaffected. Theanoparticles
ersity index Zeta potential (mV) Flurbiprofen loading (μg/mg)
0.053 −17.4 60.2
0.048 −27.6 -
Figure 1 Cytotoxicity of free or nanoparticulate flurbiprofen.
bEnd.3 cells were treated with the indicated concentrations of free
flurbiprofen (A) or PLA-flurbiprofen nanoparticles (B) for 72 hours.
The cytotoxicity was assessed after a four hour incubation with 1 ×
alamarBlue®. The absorbance was measured and the cell viability
was calculated as a percentage of absorbance in relation to vehicle
control treated cells. The data represent mean ± SEM of n ≥3. PLA,
polylactide; SEM, standard error of the mean.
Figure 2 Influence of PLA-flurbiprofen nanoparticles on the
integrity of the endothelial cell barrier. bEnd.3 cells were cultivated
on cell culture inserts in a cellZscope® device. When cells were post-
confluent, approximately 2.4 mg nanoparticles per cm2 (corresponding
to 750 μM nanoparticulate flurbiprofen) were added to the luminal side
of the endothelial cells and the TER was measured every hour by
impedance spectroscopy. PLA, polylactide; TER, transepithelial
electrical resistance.
Figure 3 Flurbiprofen is released over time from the PLA
nanoparticles. PLA-flurbiprofen nanoparticles were dissolved in an
aqueous solution at pH 7.5 and the amount of flurbiprofen in the
solution was measured by HPLC at different time points. The release
is shown as the percentage of the total amount of incorporated
flurbiprofen in the nanoparticles. PLA, polylactide.
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nanoparticles is achieved by the in vitro release of the
drug from the nanoparticles, as shown in Figure 3. Thus,
the nanoparticulate flurbiprofen exhibited a biological
activity to modulate γ-secretase in vitro comparable to
free flurbiprofen.
Cellular binding and uptake of nanoparticles
To analyze the potential of nanoparticulate flurbiprofen
to cross a cellular monolayer, we first examined the cel-
lular binding and uptake of the PLA-flurbiprofen nano-
particles by endothelial cells. Therefore, bEnd.3 cells
were incubated with the nanoparticles for four hours at
37°C and subsequently analyzed by flow cytometry
(Figure 5A). Compared to the untreated control, cellular
binding of the PLA-flurbiprofen nanoparticles wasdetected. The cellular uptake of the nanoparticles was
further studied by CLSM. Post-confluent bEnd.3 cells
were incubated with nanoparticles for one to four hours
at either 37°C or at 4°C as a control to inhibit endocyto-
sis. At 4°C, the bEnd.3 cells exhibited no signal of the
nanoparticles demonstrating that the nanoparticles were
not endocytosed (Figure 5B). However, at 37°C, the
nanoparticles were endocytosed by the bEnd.3 cells
(Figure 5C) and this uptake increased with longer incu-
bation time (Figure 5D).
Figure 4 Aβ generation in cultured cells treated with free or
nanoparticulate flurbiprofen. 7WD10 cells were treated with the
indicated concentrations of free flurbiprofen (A) or PLA-flurbiprofen
nanoparticles (B) for 48 hours. Levels of Aβ were measured by an Aβ
specific ELISA. The data represent mean ± SEM of three independent
experiments. * Statistically significant difference (P <0.05, two-way
ANOVA) between Aβ levels of vehicle-treated and drug-treated cells
are indicated. Aβ, amyloid-β; ANOVA, analysis of variance; PLA,
polylactide; SEM, standard error of the mean.
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To study the ability of PLA nanoparticles to transport
flurbiprofen across an in vitro BBB model, bEnd.3 cells
were cultivated in the luminal compartment of cell cul-
ture inserts until a post-confluent monolayer had grown
(Figure 6A). Then, 7WD10 were co-cultured abluminally
together with the bEnd.3 cells. After confirmation of the
tightness of the endothelial cell monolayer by TER
measurement, nanoparticles were added to the bEnd.3
cells at the luminal side. As a readout for the transport
of nanoparticulate NSAIDs, we collected the medium in
the abluminal compartment after 72 hours and mea-
sured the γ-secretase activity by determining the levels
of Aβ40 and Aβ42 using a specific ELISA. Furthermore,
we measured the amount of flurbiprofen by HPLC.
Luminally administered free flurbiprofen (300 μM) hadno effect on the levels of Aβ40 and Aβ42 in the abluminal
compartment (Figure 6B). We only administered 300 μM
free flurbiprofen in this experimental setup due to its cyto-
toxic potential at higher concentrations (Figure 2A). By
HPLC, we measured the concentration of flurbiprofen in
the abluminal compartment and we could detect that ap-
proximately 10% of the initial concentration was diffusing
across the endothelial cell monolayer, which was not suffi-
cient to reduce Aβ42 (Table 2). When flurbiprofen-loaded
nanoparticles were added luminally to the endothelial
cells, Aβ42 levels decreased in a concentration dependent
manner whereas the levels of Aβ40 remained unchanged
(Figure 6C). Since the IC50 for flurbiprofen induced
γ-secretase modulation is about 150 to 200 μM, we
hypothesize that the final concentration of flurbiprofen in
the abluminal compartment, most likely still bound to
nanoparticle components, is therefore sufficient to reduce
the Aβ42 levels. These results strongly indicate that the
nanoparticles were transported in this in vitro BBB model
and that the embedded flurbiprofen was able to reduce
Aβ42 levels by modulating the γ-secretase activity.
Human blood plasma corona of the nanoparticles
When nanoparticles enter a biological fluid, proteins
rapidly compete for binding to the nanoparticle surface,
leading to the formation of a protein corona that critic-
ally defines the biological identity of the particle. The
properties of such a particle-protein complex differ sig-
nificantly from those of the formulated particle. Hence,
the further biological responses of the body as well as
the biodistribution of the nanoparticles are expected to
be influenced by the nanoparticle-protein complex [34].
Therefore, the PLA nanoparticles were incubated with
human blood plasma for several time points and we ex-
amined the binding of plasma proteins to the nanoparti-
cles. The protein binding profiles were visualized by
SDS-PAGE, demonstrating that an exposure for five
minutes was already sufficient for an efficient corona
formation (Figure 7A). Also, the amount of corona pro-
teins increased over time, albeit the corona seems to
change only quantitatively rather than qualitatively. Fur-
thermore, we examined the presence of apolipoproteins
in the protein corona (Figure 7B). Apolipoproteins are
part of the circulating lipoproteins and serve as receptor
ligands for lipid and cholesterol uptake and metabolism,
and it was suggested that apolipoprotein-modified nano-
particles are able to transport drugs across the BBB
[35-38]. We observed that apolipoprotein E (ApoE)
and apolipoprotein A4 (ApoA4) are already present in
the nanoparticle-protein complex after five minutes of
exposure, and that the amount of ApoA4 slightly de-
creased and the ApoE concentrations significantly in-
creased over time. The formation of the apolipoprotein
corona on the PLA nanoparticles indicates a potential
Figure 5 Cellular binding of the PLA-flurbiprofen nanoparticles. (A) bEnd.3 cells were treated with approximately 100 μg/cm2 PLA-
flurbiprofen nanoparticles for four hours at 37°C and the cellular binding was quantified by flow cytometry. The data are shown as histograms of
the FL1-H channel (red: PLA-flurbiprofen nanoparticles, black: untreated control). (B-D) bEnd.3 cells were treated with approximately 100 μg/cm2
nanoparticles. To inhibit endocytosis, the cells were treated at 4°C (B). For the cellular uptake, cells were treated for one hour (C) or four hours
(D) at 37°C. After the incubation period, the cells were put on ice and washed with acidic PBS to remove the surface-bound nanoparticles. The
cells were fixed with paraformaldehyde and cell nuclei were stained with DRAQ5TM. Scale bar, 10 μm. PLA, polylactide.
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tein receptor transcytosis pathway [37,39].
Discussion
AD is a severe neurodegenerative disease affecting more
than 35 million people worldwide, and is characterized by
memory impairment, neurofibrillary tangles formation and
extracellular accumulation of Aβ42 in insoluble plaques.
The Aβ42 peptide is generated through the proteolytic pro-
cessing of APP, and its accumulation or increased gener-
ation is thought to be one of the primary events in the
pathogenesis of AD [12-14,40]. According to this hy-
pothesis, reduced generation or enhanced clearance of
Aβ42 peptides and plaques would be expected to modify
the disease course in AD [41]. Recently, the Aβ42 lowering
agent tarenflurbil, the R-enantiomer of flurbiprofen, failed
in a phase III clinical trial, presumably because it couldnot cross the BBB in high enough concentrations [21].
Generally, brain penetration of CNS active drugs is mostly
limited by the BBB, and several strategies have been de-
vised to overcome this barrier to deliver therapeutic drugs
to the brain [42]. To date, drug carriers, such as nanoparti-
cles, have been studied intensively for neurological disor-
ders, cancer and other diseases, and some of them are in
different trial phases or even commercially available
[43,44]. In this study, we examined the efficiency of nano-
particulate flurbiprofen to cross the BBB in order to de-
crease selectively the levels of Aβ42 peptides in the brain.
We decided to study PLA-nanoparticle formulations
because this starting material is FDA-approved, bio-
degradable and biocompatible [29,45]. In addition, we
decided to use flurbiprofen as a GSM because it is also
FDA-approved, commercially available and, most im-
portantly, its GSM activity has been studied intensively
Figure 6 Influence of free or nanoparticulate flurbiprofen on Aβ generation in an in vitro BBB model. 7WD10 cells were co-cultured
abluminal with post-confluent bEnd.3 cells in the luminal compartment (A). bEnd.3 cells were treated with the indicated concentrations of free
flurbiprofen (B) or PLA-flurbiprofen nanoparticles (C) for 72 hours. Levels of Aβ in the abluminal compartments were measured by an Aβ specific
ELISA. The data represent mean ± SEM of three independent experiments. * Statistically significant difference (P <0.05, two-way ANOVA) between
Aβ levels of vehicle-treated and drug-treated cells are indicated. Aβ, amyloid-β; ANOVA, analysis of variance; BBB, blood-brain barrier; PLA,
polylactide; SEM, standard error of the mean.
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of the PLA-flurbiprofen nanoparticles in comparison to
free flurbiprofen was investigated. Compared to free flur-
biprofen, the PLA-flurbiprofen nanoparticles did not
affect cell viability. Even if high amounts of nanoparti-
cles were administered to the endothelial cells, and in-
cluding that the nanoparticles may sediment in the
culture medium on the surface of the cells which may
lead to different local concentrations, these amounts didTable 2 Concentration of flurbiprofen in the abluminal comp
μM luminally administered μM abluminally m
300 μM flurbiprofen 41.
300 μM PLA-flurbiprofen nanoparticles 31.
450 μM PLA-flurbiprofen nanoparticles 46.
600 μM PLA-flurbiprofen nanoparticles 63.
750 μM PLA-flurbiprofen nanoparticles 83.not perturb the integrity of an endothelial barrier. Thus,
the embedding of flurbiprofen in nanoparticles disguised
its cytotoxic potential which enables the application of
higher concentrations on endothelial cells without any
cytotoxic potential. The cellular binding and uptake of the
nanoparticles was observed by flow cytometry and CLSM.
These data confirmed the cellular binding as well as a
time-dependent uptake of the nanoparticles by endothelial
cells. Next, the in vitro release of flurbiprofen from theartment measured by HPLC






Figure 7 ApoE and ApoA4 are part of the protein corona of the
PLA nanoparticles. PLA nanoparticles were incubated with equal
amounts of human plasma for different time points and the
nanoparticles-protein complexes were analyzed by SDS-PAGE
(A) and Western blot (B). Human blood plasma served as control
(ctrl.). Apo, apolipoprotein; PLA, polylactide.
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drug is constantly released over the time. Consequently,
we examined the biological activity of the nanoparticulate
flurbiprofen compared to free flurbiprofen in the APP
overexpressing cell line 7WD10. Free flurbiprofen specifi-
cally decreased Aβ42 levels with a maximal effect size of
approximately 70%, in good agreement with previous stud-
ies [17,19]. For the PLA-flurbiprofen nanoparticles, a simi-
lar decrease in Aβ42 levels was detected. Since flurbiprofen
is released constantly over time from the PLA nanoparti-
cles, its biological activity to modulate γ-secretase activity
in vitro was comparable to free flurbiprofen. Based on
these observations that the PLA-flurbiprofen nanoparticles
were able to lower Aβ42 levels and were endocytosed
by endothelial cells, we studied their transport in an
in vitro BBB model. In these experiments, the endothelial
cells were cultured luminally on cell culture inserts (repre-
senting the blood side) with the 7WD10 cell line in the
abluminal compartment (representing the brain side). In
this experimental setup, free flurbiprofen did not reduceAβ42 levels, because it was not sufficiently transported
across the endothelial cell monolayer at high enough con-
centration. This is in agreement with phase I dosing studies
of R-flurbiprofen in humans [46]. In these studies, healthy
volunteers were treated for 21 days with up to 800 mg
twice daily of R-flurbiprofen. Maximal plasma concentra-
tions of R-flurbiprofen up to 185 μM were measured, well
in the range of the Aβ42-lowering activity of flurbiprofen in
tissue culture experiments. However, flurbiprofen concen-
trations in the cerebrospinal fluid (CSF) of the volunteers
were found to be more than 100-fold lower with an aver-
age CSF to plasma ratio of 0.5%. No significant changes in
CSF Aβ42 levels were observed in R-flurbiprofen treated in-
dividuals compared to placebo controls. In the failed Phase
III clinical study of R-flurbiprofen, CSF drug concentration
were not measured but the highest dose administered in
the trial was identical to the phase I study, predicting simi-
larly low brain concentrations [21]. Importantly, we could
detect a significant decrease of Aβ42 levels for the nanopar-
ticulate flurbiprofen. In earlier studies, we were able to
demonstrate that drug-loaded nanoparticles exhibited a
higher biological activity than the free drug alone [47]. The
nanoparticulate drug had a lower IC50 value than the free
drug molecule resulting in a higher efficiency of the nano-
particulate formulation. Furthermore, the nanoparticles
may gradually sediment in the culture medium on the sur-
face of the cells, which can locally lead to higher concen-
trations of the nanoparticulate flurbiprofen compared to
free flurbiprofen. For the HPLC measurements, the total
capacity of the abluminal compartment was used and the
total concentration of free or nanoparticulate flurbiprofen
was measured. Thus, total concentration of the nanoparti-
culate flurbiprofen may not be higher compared to free
flurbiprofen, but if the sedimentation of the nanoparticles
is taken into account, the concentrations of the nanoparti-
culate flurbiprofen can be locally higher resulting in signifi-
cantly decreased levels of Aβ42. The embedding of
flurbiprofen into nanoparticles not only disguises its cyto-
toxic potential, it further enables the administration
of higher drug concentrations resulting in a sufficient
transport of the drug across the endothelial cell monolayer.
These data provide a proof of principle showing that
even NSAIDs with low GSM activity can efficiently lower
Aβ42 levels if transported sufficiently across the BBB. As a
potential transport mechanism we would like to highlight
the presence of the lipoproteins ApoA4 and ApoE in
the protein corona of the nanoparticles. In biological fluids,
proteins and other biomolecules bind to the surface of
the nanoparticles and build a corona which determines
their biological properties. For instance, members of
the apolipoprotein family enable the endocytotic uptake
through lipoprotein receptors. In a recent study, we were
able to show that ApoE-modified nanoparticles were
actively endocytosed by endothelial cells and that the
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involved in this process [37]. Thus, the transport of the
nanoparticulate flurbiprofen may be facilitated by the
surface-bound proteins mimicking endogenous lipopro-
teins via endocytosis by transporters such as LRP1.Conclusions
Over the past years, the application of nanotechnology-
based strategies for the treatment or diagnosis of AD has
been investigated by many groups [43,48]. Some ap-
proaches, like this study, focused on the encapsulation of
molecules into nanoparticles for delivery to the brain;
others dealt with a reduction of amyloid plaques toxicity
or focused on the early detection of the disease [49]. In
this study, we could show that after embedding in
polymeric nanoparticles, flurbiprofen can be transported
across the BBB and retains its biological activity. However,
some improvements and optimizations of the nanoparti-
cles are required for future applications. The use of other
GSMs with higher potency, or surface modifications such
as coupling the nanoparticles with peptides or ligands,
which can achieve a higher bioavailability or a specific tar-
geting to the brain, are just some examples for achievable
improvements [15,20]. To date, an enormous amount of
work has been invested in the sophisticated surface-
functionalization of drug carriers to improve their target-
ing and/or bioactivity, but the potential impact of the
protein corona on the success or failure of these strategies
has been mostly neglected so far [34,50,51]. However,
we show for the first time that the blood plasma protein
corona on PLA nanoparticles is established rapidly, is
complex and appears to change predominantly only quan-
titatively over time. The surface-functionalization of nano-
particles with apolipoproteins has been shown to facilitate
translocation through the BBB [37,38,52], and we assume
that the observed ‘natural functionalization’ of the PLA
nanoparticles with ApoE and ApoA4 may facilitate the
BBB transport of the nanoparticulate flurbiprofen via
endocytosis using transporters such as LRP1 [37]. Whether
further surface modifications may increase BBB transport
remains to be investigated. The surface-functionalization
of drug carriers is labor and cost-intensive and therefore
often limited to (pre)clinical studies in nanobiomedicine.
Since the protein corona is established in physiological
environments, this ‘natural biofunctionalization’ should
be exploited to improve the bioactivity of drug carriers
to overcome these limitations.
Taken together, we were able to show that the modifica-
tion of usually nonpermeable drugs via embedding in
nanoparticles results in an efficient transport across an
endothelial cell monolayer and that these nanotechnology-
based strategies are very promising to generate novel thera-
peutic options for AD and other CNS diseases.Abbreviations
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